Research and Funding

Funding Opportunities

National Institute on Aging: Revision Requests for Active Alzheimer's Disease Centers (P50)

Funding Number: PA-12-170
Funding Type: PA
Release Date: April 20, 2012
Expiration Date: May 8, 2015
Web Site:


The National Institute on Aging (NIA) invites current NIA Alzheimer's Disease Center directors to submit revision applications to expand the scope of the current award. The proposed topic must both be related to the current focus of the Center and be relevant to the mission of the Center Program and the National Institute on Aging. The revision may propose to create new cores and/or projects. Revision applications should be submitted as appropriate to the science being proposed. So, for example, if two different ideas are being considered then they should be submitted as two different revisions. On the other hand, if a single concept spans several cores or projects then that concept should be submitted as a single revision. Projects may focus on areas such as preclinical etiology, genetics, pathogenesis, epidemiology, diagnosis, therapeutic interventions including small scale clinical trials, patient management, and caregiver issues.  Projects that are translational, focusing on drug discovery or preclinical drug development for AD or other neurodegenerative diseases are also encouraged. These may focus on: validation of new therapeutic targets, development of new assays or animal models, screening of candidate compounds or acquisition of preliminary preclinical efficacy data. A project should be similar in quality to small R01 grants and subprojects of program project grants. A core would augment or enhance the present capabilities of investigators using center resources to make possible new activities at the center itself as well as for other grants affiliated with the center.  There should be a detailed discussion of the project(s) that will use resources of an additional core. Some examples of research support that core components could provide are: (1) development of tools and/or technologies used for therapy development; (2) imaging; (3) tissue and/or cell culture facilities; (4) complex instrumentation, e.g., electron microscopy, mass spectrometry, electrophysiology; (5) sequencing or microarray facilities; (6) transgenic animal or cell preparation; (7) genetics; and (8) caregiving.

A revision application may be submitted only after the Parent P50 project has been funded.